(Source: Xencor Inc) MONROVIA, Calif., Oct. 3, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that preliminary data from an ongoing open-label Phase 2 study of XmAb5871 in patients with IgG4-Related Disease will be presented during an oral presentation on Sunday, November 13 at the American College of Rheumatology (ACR) 2016 Annual Meeting. An abstract of the presentation is available on the ACR conference website at: http://acrabstracts.org/. Information contained in the abstract was at the time of...
↧